Genistein Combined with FOLFOX or FOLFOX-Avastin for treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study
ID Number 13-1697Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
We hypothesize that genistein will reduce chemotherapy resistance and lead to improved response rates in colon and rectal cancer patients receiving 5FU and oxaliplatin based therapy as first line treatment for metastatic disease. The aim of the study is to treat patients with newly diagnosed stage IV colorectal cancer with genistein in addition to standard of care treatments FOLFOX or FOLFOX-Avastin.
Recruiting Patients: Yes